Transgene, ProBioGen Enter License Agreement for AGE1.CR.pIX Suspension Cell Line

Partnership aims to advance individualized cancer vaccine development.

Author Image

By: Charlie Sternberg

Associate Editor

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a CDMO focused on biologics, vaccines and viral vectors, have entered into a license agreement for ProBioGen’s AGE1.CR.pIX suspension cell line.   This partnership aims to add value by combining ProBioGen’s specific production technology with the manufacturing capabilities of Transgene’s individualized cancer vaccine program and its myvac platform.   ProBioGen’s AGE1...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters